Results 121 to 130 of about 1,741 (166)
Do biologics improve health outcomes in children with severe asthma? A cohort study. [PDF]
ERJ Open ResQuach S +6 more
europepmc +1 more source
Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment. [PDF]
J Clin MedPastore D +11 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab
Journal of Allergy and Clinical Immunology: in PracticeTezepelumab has shown promising efficacy for adult patients with severe asthma since its approval. However, the post-marketing safety evaluation of tezepelumab is currently lacking.To investigate the post-marketing safety of tezepelumab based on the US Food and Drug Administration Adverse Event Reporting System database.Adverse events (AEs) reported ...
Cuilian Guo
exaly +3 more sources
Drugs of Today, 2022
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), known as "alarmins".
Nolasco, Santi +4 more
openaire +2 more sources
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), known as "alarmins".
Nolasco, Santi +4 more
openaire +2 more sources
Tezepelumab in the Treatment of Uncontrolled Severe Asthma
Annals of Pharmacotherapy, 2022Objective: To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma. Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms ...
Jacqueline Feist +2 more
openaire +2 more sources
Drugs, 2022
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class human IgG2λ monoclonal antibody that inhibits the action of TSLP. Administered subcutaneously, it is being developed by Amgen and AstraZeneca for the treatment of asthma ...
openaire +2 more sources
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class human IgG2λ monoclonal antibody that inhibits the action of TSLP. Administered subcutaneously, it is being developed by Amgen and AstraZeneca for the treatment of asthma ...
openaire +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
The effectiveness and value of tezepelumab for severe asthma.
Journal of managed care & specialty pharmacy, 2022DISCLOSURES: Drs Rind, Campbell, Pearson, Ms Herce-Hagiwara, Ms Fluetsch, and Ms Herron-Smith report grants from Arnold Ventures; Kaiser Foundation Health Plan, Inc; The Patrick and Catherine Donaghue Medical Research Foundation; Blue Cross Blue Shield of Massachusetts; and California Healthcare Foundation during the course of this study.
David M, Rind +7 more
openaire +3 more sources
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)
European Respiratory Journal, 2021Rationale and objectives Thymic stromal lymphopoietin (TSLP), an epithelial upstream cytokine, initiates production of type-2 (T2) cytokines with eosinophilia and possibly airway hyperresponsiveness (AHR) in asthma. This study aimed to determine whether tezepelumab (a human monoclonal antibody targeting TSLP) decreases AHR and airway inflammation in ...
Sverrild, Asger +9 more
openaire +3 more sources
Tezepelumab as add‐on treatment for severe asthma
Prescriber, 2023Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.
openaire +1 more source